Skip to content

Study on the safety and efficacy of esketamine-cipepofol-remifentanil anesthesia in non-endotracheal intubation ERCP surgery

Study on the safety and efficacy of esketamine-cipepofol-remifentanil anesthesia in non-endotracheal intubation ERCP surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124188
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-11
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common bile duct stones

Interventions

Control Group:The same volume of normal saline + Propofol at 3 mg/kg/h + Remifentanil at 1.8 µg/kg/h.
Group Three:Esketamine 0.1mg/kg/h + Cipepofol 0.8mg/kg/h + Remifentanil 1.8µg/kg/h.

Sponsors

Huai'an First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with gastrointestinal disorders who underwent ERCP surgery in our hospital; 2. Patients with American Society of Anesthesiologists (ASA) grade I-II; 3. Patients aged 20-65 years old, with a BMI of no more than 30%.

Exclusion criteria

Exclusion criteria: 1. Patients with liver or kidney dysfunction or electrolyte imbalance; 2. Patients who received antidepressant drugs, sedative analgesic drugs within two weeks before the surgery. 3. Patients with contraindications to the use of related drugs;

Design outcomes

Primary

MeasureTime frame
respiratory depression;cognitive function assessmet;body movement response;Observer’s assessment of alertness/sedation;

Secondary

MeasureTime frame
Quality of anesthesia recovery;

Countries

China

Contacts

Public ContactLijun An

Huai'an First People's Hospital

hayyalj@njmu.edu.cn+86 13861559992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026